European Commission Question & Answer Document for Patients Builds Trust and Understanding on Biosimilar Medicines across Europe

25 October 2016

Today, the European Commission published a Q&A for patients on […]

NOR-SWITCH Study: Another Significant Example of Positive Real World Evidence on Physician-led Switching to Biosimilar Medicines

18 October 2016

Today at the United Gastro-Enterology (UEG) week in Vienna, the NOR-SWITCH […]

European Commission Strongly Recommends the Use of Generic and Biosimilar Medicines to Ensure the Sustainability of Healthcare Systems

14 October 2016

Medicines for Europe welcomes the publication of the ‘Joint Report […]

Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market

19 September 2016

Biosimilar medicines provide a tremendous opportunity for governments throughout Europe […]

Commission to Look into ‘Skyrocketing’ EU Drug Prices, Availability, and Patient Access

20 June 2016

Industry Welcomes the European Commission Workshop on the Uptake of Biosimilar Medicines

20 June 2016

The European pharmaceutical industry welcomes the workshop organised today by […]

European Health Ministers Call for More Competition in Pharmaceutical Markets

17 June 2016

Medicines for Europe will engage rapidly with Health Ministers across […]

IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly

15 June 2016

Biosimilar Medicines for Rheumatologists: Bridging the Gap between Regulatory Science and Medical Societies

10 June 2016

Over the past decade, biosimilar medicines have generated more than […]

Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda

9 June 2016

During the next two days, the key pharmaceutical industry leaders […]